Select Page

Opportunities and Challenges in Clinical Studies of Generic Anticancer Tyrosine Kinase Inhibitors

PRESENTED TO: BioPharma Services Inc.
PRESENTED BY: N. RAYAD, N. GHARAVI, J. HE, F. TRABELSI

PURPOSE

Opportunities and Challenges in Clinical Studies of Generic Anticancer Tyrosine Kinase Inhibitors – Tyrosine kinase inhibitors (TKIs) are multi-targeted anticancer drugs with high activity towards several families of receptor and nonreceptor tyrosine kinases involved in angiogenesis, tumor growth and metastatic progression of cancer.

Many of these will be running off-patent, sequentially, in the next few years. Bioequivalence (BE) studies are needed for the development and regulatory approval of generic products of TKIs.

Biopharma Services Inc. (BPSI) has a proven track record and experience with BE studies on TKIs and other oncology drug products.

To access the entire publication and view the full resolution PDF, please complete the form.

Opportunities and Challenges in Clinical Studies of Generic Anticancer Tyrosine Kinase Inhibitors

Download Publication

BioPharma Services Inc. is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below to say how you would like us to contact you:
In order to provide you the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please tick the checkbox below.
You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Popular Posts

View More